CytoAgents, Inc

As a clinical-stage biotech company, CytoAgents is making tremendous strides in the battle against Cytokine Release Syndrome (CRS), a dangerous overreaction of the immune system. Our drug candidate will increase patient safety and make important treatments such as CAR T-cell therapy safer for patients. We invite you to join us as we move closer to our goal. Follow our progress here: https://cytoagents.com/ #cytokinereleasesyndrome #cytokines #crs #cartcelltherapy Teresa Whalen, RPh

CAR T-cell therapy is expanding, which is a positive development for patients with certain types of cancer. But as this article points out, "Despite its success, CAR T-cell therapy faces several challenges." One of the more serious challenges is the risk of a potentially deadly side effect known as Cytokine Release Syndrome (CRS), which is an overreaction of the immune system. CytoAgents is developing a solution to treat CRS, which will make CAR T-cell therapy safer for patients. Learn about it here: https://cytoagents.com/ #cytokinereleasesyndrome #crs #cytokines #cartcelltherapy Teresa Whalen, RPh

The CytoAgents team is working on bringing to market novel treatments for the symptoms associated with Cytokine Release Syndrome (CRS), an overreaction of the immune system, commonly known as Cytokine Storm. Led by CEO Teresa Whalen, RPh and a team of seasoned healthcare executives, clinical leaders, and biotech investors, CytoAgents is poised to make a significant impact in patient safety and the availability of important treatment modalities. Learn more: https://cytoagents.com/ #biotechnology #biotech #biotechleadership #healthcareleadership

CytoAgents is committed to developing a safe and effective treatment for Cytokine Release Syndrome (CRS), which an overreaction of the immune system caused by excessive, prolonged cytokine production. Our approach to treatment focuses on reducing the destructive impact of CRS while leaving the necessary immune function intact. Our drug will make important treatments like CAR T-cell therapy safer and more accessible for patients. Learn about our science here: https://lnkd.in/eyd7hsFe #cytokinereleasesyndrome #crs #cytokines #cartcelltherapy Teresa Whalen, RPh

This article on the Johnson & Johnson website provides an excellent overview of the current state and future promise of CAR T-cell therapy for the treatment of certain types of cancer. While CAR T-cell therapy can be a life-saving treatment, significant risks still remain. #CytoAgents is working to make CAR T-cell therapy safer for patients by developing a solution for a common side effect known as Cytokine Release Syndrome (CRS), which is an overreaction of the immune system. Learn abort CRS and CytoAgents' solution here: https://lnkd.in/eyd7hsFe #cytokinereleasesyndrome #crs #cytokines #cartcelltherapy Teresa Whalen, RPh

Building a company that provides a life-changing product requires tenacity, teamwork, and an unyielding commitment to the mission. Our mission is to develop a novel therapy for the treatment of Cytokine Release Syndrome (CRS), which will make modern immunotherapies such as CAR T-cell therapy safer for patients. Led by CEO Teresa Whalen, RPh, CytoAgents is closer than ever to fulfilling our mission. Learn about our solution and journey here: https://cytoagents.com/ #biotech #biotechnology #healthcareleadership #leadership #crs

CytoAgents' mission: To develop a novel therapy for the treatment of Cytokine Release Syndrome (CRS), a dangerous and potentially life-threatening overreaction of the immune system, commonly known as Cytokine Storm. CytoAgents is conducting its Phase 1b/2a clinical trial to treat CRS in patients receiving CAR T-cell therapy in oncology. Finding an effective solution to CRS will make CAR T-cell therapy safer for patients. Learn more here: https://lnkd.in/eyd7hsFe #cytokinereleasesyndrome #crs #cytokines #cartcelltherapy Teresa Whalen, RPh

Researchers are continuing their efforts to expand access to CAR T-cell therapy for patients with certain types of cancer. CytoAgents is also focused on expanding patient access to this life-saving treatment by addressing a dangerous side effect known as Cytokine Release Syndrome (CRS), which is an overreaction of the immune system. Learn how CytoAgents' solution will make CAR T-cell therapy safer for patients: https://cytoagents.com/ #cytokinereleasesyndrome #crs #cytokines #cartcelltherapy Teresa Whalen, RPh

We are making great strides in 2025! Led by CEO Teresa Whalen, RPh, CytoAgents is moving steadily toward achieving our goal of developing a novel therapy for the treatment of Cytokine Release Syndrome (CRS), a dangerous and potentially life-threatening overreaction of the immune system, commonly known as Cytokine Storm. Learn about our mission, solution, and progress here: https://cytoagents.com/ #biotech #biotechnology #healthcareleadership #leadership #crs

There is a lot of information published about the powerful effects of CAR T-cell therapy as a treatment for certain types of cancer, but did you know that more than two-thirds of CAR T-cell therapy patients experience a potentially dangerous side effect known as Cytokine Release Syndrome (CRS)? CytoAgents is working toward developing an effective solution to treat CRS, which will make CAR T-cell therapy safer for patients. Learn about CytoAgents and our solution here: https://cytoagents.com/ #cytokinereleasesyndrome #crs #cytokines #cartcelltherapy Teresa Whalen, RPh